BD Board Declares Dividend and Expands Share Repurchase
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), one of the foremost global medical technology companies, has recently announced an exciting financial update. The board has declared a quarterly dividend amounting to $1.05 per common share, which is payable on the upcoming date of March 31, 2026.
This substantial dividend will be available to shareholders who are on record by March 10, 2026. With this move, BD indicates an annual dividend rate of $4.20 per share, reflecting the company's steady commitment to returning value to its shareholders.
Stock Repurchase Program Details
BD's board also revealed that the company has successfully repurchased $250 million worth of its stock so far in fiscal 2026. In addition, the board has authorized an expansion of its share repurchase program, enabling the company to buy back up to 10 million shares of its common stock. This is in addition to the shares already permitted for repurchase under earlier board authorizations from 2021 and 2025.
These authorizations empower BD to acquire shares through various means, including open market purchases, private negotiations, or other methods deemed appropriate. The management retains the discretion to determine the timing, manner, number, and value of any shares repurchased, based on factors like market conditions and the company’s economic landscape.
About BD and Its Commitment to Health
BD operates as one of the largest global medical technology companies striving to improve healthcare worldwide. They focus on advancing medical discovery, diagnostics, and the delivery of care. BD’s mission extends to supporting healthcare heroes by developing innovative technologies, services, and solutions that enhance both patient therapy and healthcare processes.
With a workforce exceeding 70,000 passionate employees, BD is committed to enhancing the safety and efficiency of healthcare delivery. Their innovative contributions aim to empower laboratory scientists to accurately detect diseases and support researchers in developing advanced diagnostics and therapeutics.
Global Reach and Partnerships
BD has established a robust presence across nearly every country and collaborates with various organizations worldwide to confront significant health challenges. Their commitment to working closely with healthcare professionals enables the enhancement of medical outcomes, reduction of costs, and improvement of accessibility to care.
With their ongoing focus on innovation, BD is brilliantly positioned to address the evolving needs of the global health landscape. As the company embraces emerging health technologies, it continues to lead the way in transforming health care delivery through advanced medical solutions.
Contact Information
For further inquiries, BD invites stakeholders to connect with their communications and investor relations teams. Media inquiries can be directed to Matt Marcus, VP of Public Relations, while investor-related questions can reach Shawn Bevec, SVP of Investor Relations.
Frequently Asked Questions
What is the declared dividend amount per share by BD?
BD has declared a quarterly dividend of $1.05 per common share.
When will the dividends be paid to shareholders?
The dividends will be paid on March 31, 2026, to holders of record by March 10, 2026.
How much stock has BD repurchased so far in fiscal 2026?
BD has repurchased $250 million worth of its stock to date in fiscal 2026.
What is the total number of shares BD is authorized to repurchase?
The board has authorized the repurchase of up to 10 million additional shares of BD common stock.
Who can I contact for media or investor inquiries at BD?
Media inquiries can be sent to Matt Marcus, while investor questions should be directed to Shawn Bevec.
